Current stock page

Catalysts

ASND Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ASNDAscendis Pharma A/S

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$275.39+$8.32 (+3.12%)

Latest quote

  • Momentum
    75
  • Value
    66
  • Quality
    71
  • Risk resilience
    72
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 10, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 72/100

Momentum 75/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 16.31%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 75/100AIQ Edge 9/10 Strong Relative Position
Beat rate
63%
5 of 8 reported periods
Average surprise
-109.9%
Across covered historical reports
Latest result
+38.7%
Nov 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 12, 2026—$0.89$1.24+38.7%$409.4M$418.76M
Aug 13, 2026—$1.71$3.29+92.4%$376.75M$387.48M
May 7, 2026—$0.19$0.32+70.6%$308.93M$284.92M
Feb 11, 2026—-$0.06-$0.64-966.7%$292.26M$344.84M
Nov 12, 2025—-$0.41-$1.17-185.4%$302.6M$250.22M
Aug 7, 2025—-$1.42-$0.93+34.5%$233.12M$186.09M
May 1, 2025—-$1.56-$1.66-6.4%$153.48M$110.67M
Feb 12, 2025—-$1.20-$0.68+43.3%$125.42M$180.09M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
21
Buy
1
Hold
12-month analyst target
$311.67
+13.17% versus current price
Based on 22 analyst observations. Targets are estimates, not predictions.
Low target
$268.00
-2.68% vs latest price
Average target
$311.67
+13.17% vs latest price
High target
$352.00
+27.82% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 10, 2027

Next known earnings or reporting date.

EPS estimate$1.40

Current analyst expectation for the upcoming report.

Revenue estimate$507.81M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score75

Where event reaction would show up first.

AIQ score72/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
22
Average target
$311.67
Target upside
13.17%
Target range
$268.00 - $352.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
gurufocus.com · Nov 12, 2026

Q3 2026 Ascendis Pharma A/S Earnings Call Transcript

Nov 12, 2026 / 01:00PM GMTOperator Ladies and gentlemen, thank you for standing by. Welcome to the third quarter 2026 Ascendis Pharma earnings conference call.

seekingalpha.com · Nov 12, 2026

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q3 2026 Earnings Call November 12, 2026 8:00 AM ESTCompany ParticipantsChad Fugure - Vice President of Investor RelationsJan...

insidermonkey.com · Sep 21, 2026

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares.

rttnews.com · Sep 15, 2026

Ascendis Pharma Stock Falls 13% Over Share Repurchase Program Authorization

Ascendis Pharma A/S (ASND) is down 13.07 percent, losing $34.64 to $230.28 on Tuesday. The move comes after the biopharmaceutical company announced that its Board of Directors authorized a share repurchase program of up to $400 million of its ordinary shares.

finance.yahoo.com · Sep 12, 2026

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

Open full news and sentiment

ASND Catalysts FAQ

What are the next catalysts for ASND stock?

ASND's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ASND stock?

Upcoming events that could move ASND include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ASND's next earnings report affect the stock?

ASND's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ASND stock higher?

ASND could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ASND stock?

ASND could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.